7 completed, 1 terminated, 1 withdrawn. 3 Phase 1, 2 Not applicable, 1 Early Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Withdrawn 1 |
| Not applicable | 2 | Completed 1, Terminated 1 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow Stage IIC Ovarian Cancer: new trials by email Literature Review of Stage IIC Ovarian Cancer trials Research Report on Stage IIC Ovarian Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Laboratory Biomarker Analysis, Recombinant NY-ESO-1 Protein, Sirolimus - Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2017-12-08 | 2018-05-01 | |
| Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer Diagnostic Microscopy, Fluorescein Sodium Injection, Laboratory Biomarker Analysis - Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma | Early Phase 1 | Completed | Roswell Park Cancer Institute | 19 | 2017-11-06 | 2021-10-06 |
| Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors Informational Intervention - Stage I Breast Cancer, Stage I Cervical Cancer | Not applicable | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 40 | 2015-08-01 | 2025-04-29 |
| Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Cyclophosphamide, Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha Peptide Vaccine - Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma | Phase 1 | Completed | Mayo Clinic | 24 | 2012-07-24 | 2024-08-21 |
| Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study - Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma | Phase 1 | Completed | Roswell Park Cancer Institute | 18 | 2012-03-01 | 2016-10-04 |
| Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer Adjuvant Therapy, Aprepitant, Carboplatin - Nausea and Vomiting, Ovarian Brenner Tumor | Not applicable | Terminated | Gynecologic Oncology Group | 4 | 2011-06-01 | 2018-05-22 |
| OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission Laboratory Biomarker Analysis, Polyvalent Antigen-KLH Conjugate Vaccine, Saponin-based Immunoadjuvant OBI-821 - Stage IA Fallopian Tube Cancer, Stage IA Ovarian Cancer | Phase 2 | Completed | Gynecologic Oncology Group | 171 | 2010-07-01 | 2017-09-13 |
| Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Cognitive Assessment, Quality-of-Life Assessment - Cognitive Side Effects of Cancer Therapy, Malignant Ovarian Epithelial Tumor | Completed | Gynecologic Oncology Group | 247 | 2010-04-01 | 2018-04-12 | |
| Collecting Tumor Samples From Patients With Gynecological Tumors Laboratory Biomarker Analysis - Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor | Completed | Gynecologic Oncology Group | 275 | 1992-06-01 | 2016-10-28 |
Ovarian Neoplasms (9) · Fallopian Tube Neoplasms (7) · Breast Neoplasms (3) · Brenner Tumor (3) · Melanoma (2) · Uterine Cervical Neoplasms (2) · Astrocytoma (1) · Brain Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Dysgerminoma (1) · Esophageal Neoplasms (1) · Gestational Trophoblastic Disease (1) · Glioblastoma (1)
Adnexal Diseases (9) · Endocrine Gland Neoplasms (9) · Endocrine System Diseases (9) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Genital Diseases (9) · Genital Diseases, Female (9) · Genital Neoplasms, Female (9) · Gonadal Disorders (9) · Neoplasms (9) · Neoplasms by Site (9) · Ovarian Diseases (9) · Urogenital Diseases (9) · Urogenital Neoplasms (9) · Fallopian Tube Diseases (7)
Sirolimus (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Aprepitant (1) · Calcium Dobesilate (1) · Carboplatin (1) · Chemotherapy, Adjuvant (1) · Cisplatin (1) · Cyclophosphamide (1) · Dexamethasone (1) · Fluorescein (1) · Fluoresceins (1) · Granisetron (1) · Mental Status and Dementia Tests (1) · Platinum (1) · auricularum (1)
Gynecologic Oncology Group (4) · Roswell Park Cancer Institute (3) · Mayo Clinic (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1)
United States (9)
Kunle Odunsi (2) · Andrea Barsevick, PhD (1) · Emese Zsiros, MD (1) · Lisa Hess (1) · Matthew S. Block, M.D., Ph.D. (1) · Michael Cibull (1) · Paul Sabbatini (1) · Steven Plaxe (1)
P30CA016056 (2), R01CA158318 (2), U10CA101165 (2), U10CA180868 (2), U10CA027469 (1)